Search for risk factors influencing the occurrence of infusion reaction after initial treatment with obinutuzumab was written by Kuromatsu, Makoto;Kajita, Takashi;Taruno, Mai;Nishikawa, Yutaka;Akasaka, Takashi;Okuno, Tomoyuki. And the article was included in Iryo Yakugaku in 2021.Electric Literature of C16H21Cl2N3O2 The following contents are mentioned in the article:
Obinutuzumab, a novel glyco-engineered anti-CD20 monoclonal antibody, has been developed to have superior efficacy to rituximab. Although obinutuzumab frequently causes infusion reactions (IR) during initial administration, there have been few reports about the frequency and risk factors for IR. In this study, the author investigated the frequency of clin. relevant IR during obinutuzumab administration and explored the risk factors associated with obinutuzumab-induced IR. The author included patients who were administered obinutuzumab for CD20+ B-cell non-Hodgkin lymphoma treatment at the Department of Hematol. in Tenri Hospital from Sept. 2018 to Sept. 2020. Twenty-five patients were included (13 men and 12 women) and their median age was 68 (49 – 81 years). Nine (36%) of these patients developed IR (grade ≥ 2). Comparison of patient characteristics between IR and non-IR groups showed that the incidence of IR during obinutuzumab administration was related to soluble interleukin-2 receptor (sIL-2R) and lactate dehydrogenase (LDH) levels. The results of ROC curve anal. revealed the cut-off values of sIL-2R and LDH were 3,201 U/mL and 260 U/L, resp., and AUC of ROC curve for sIL-2R and LDH were estimated at 0.75 and 0.72, resp. The higher IR incidence was detected when sIL-2R levels exceeded 3.201 U/mL. In addition, the number of patients who developed IR at sIL-2R ≥ 3,201 U/mL and/or LDH ≥ 260 U/L was larger than that at sIL-2R ≥ 3,201 U/mL. The combined biomarker, SIL-2R and LDH may be useful for prediction of the occurrence of IR after the initial administration of obinutuzumab. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Electric Literature of C16H21Cl2N3O2).
4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Many drugs contain an imidazole ring, such as certain antifungal drugs, the nitroimidazole series of antibiotics, and the sedative midazolam.Electric Literature of C16H21Cl2N3O2
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem